NEW YORK (GenomeWeb News) – Warnex Medical Laboratories has licensed from Xenomics the rights to use a marker for acute myeloid leukemia in a diagnostic test, Xenomics said Thursday.

The agreement gives Warnex nonexclusive rights in Canada to use a recently discovered mutation in the NPM1 gene in a lab service to help doctors diagnose, stratify, and monitor AML patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.